Trials / Terminated
TerminatedNCT00958269
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Phenomix · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of dutogliptin in Type 2 diabetic subjects with moderate or severe renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dutogliptin | 100 mg QD |
| DRUG | dutogliptin | 200 mg QD |
| DRUG | placebo | |
| DRUG | sitagliptin | 25 mg QD |
| DRUG | sitagliptin | 50 mg QD |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-09-01
- Completion
- 2011-11-01
- First posted
- 2009-08-13
- Last updated
- 2010-02-03
Locations
43 sites across 3 countries: United States, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00958269. Inclusion in this directory is not an endorsement.